3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
7
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Breast Diseases
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
Bevacizumab
37
Paclitaxel
33
Carboplatin
25
pembrolizumab
23
Specimen Handling
21
olaparib
19
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
liposomal doxorubicin
16
Cyclophosphamide
16
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Fulvestrant
9
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Disulfides
8
Doxorubicin
7
palbociclib
6
aldesleukin
6
Surveys and Questionnaires
6
Oxaliplatin
5
Letrozole
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Gonadotropin-Releasing Hormone
×
90 days
×
Clear all
NCT04931342
2026-06-08
BOUQUET
Hoffmann-La Roche
Phase 2
Active not recruiting
176 enrolled